Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer - PubMed (original) (raw)

Review

Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer

Gordon J S Rustin et al. Clin Cancer Res. 2004.

No abstract available

PubMed Disclaimer

Similar articles

• Use of CA-125 to assess response to new agents in ovarian cancer trials.
  Rustin GJ. Rustin GJ. J Clin Oncol. 2003 May 15;21(10 Suppl):187s-193s. doi: 10.1200/JCO.2003.01.223. J Clin Oncol. 2003. PMID: 12743133 Review.
• Monitoring ovarian cancer: CA125 trial stirs controversy.
  Chitale R. Chitale R. J Natl Cancer Inst. 2009 Sep 16;101(18):1233-5. doi: 10.1093/jnci/djp316. Epub 2009 Sep 8. J Natl Cancer Inst. 2009. PMID: 19738165 No abstract available.
• Progressive epithelial ovarian carcinoma. Prognostic factors and clinical management.
  Grønlund B. Grønlund B. Dan Med Bull. 2006 Aug;53(3):232-57. Dan Med Bull. 2006. PMID: 17092448 Review. No abstract available.
• A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy.
  Zheng Y, Katsaros D, Shan SJ, de la Longrais IR, Porpiglia M, Scorilas A, Kim NW, Wolfert RL, Simon I, Li L, Feng Z, Diamandis EP. Zheng Y, et al. Clin Cancer Res. 2007 Dec 1;13(23):6984-92. doi: 10.1158/1078-0432.CCR-07-1409. Clin Cancer Res. 2007. PMID: 18056174

Cited by

• CA-125 variation in acute heart failure: a single-centre analysis.
  Lourenço P, Cunha FM, Elias C, Fernandes C, Barroso I, Guimarães JT, Bettencourt P. Lourenço P, et al. ESC Heart Fail. 2022 Apr;9(2):1018-1026. doi: 10.1002/ehf2.13758. Epub 2022 Jan 5. ESC Heart Fail. 2022. PMID: 34989167 Free PMC article.
• Overexpression of Cancer-Associated Genes via Epigenetic Derepression Mechanisms in Gynecologic Cancer.
  Jeong HM, Kwon MJ, Shin YK. Jeong HM, et al. Front Oncol. 2014 Feb 4;4:12. doi: 10.3389/fonc.2014.00012. eCollection 2014. Front Oncol. 2014. PMID: 24551595 Free PMC article. Review.
• Pegylated liposomal doxorubicin in ovarian cancer.
  Strother R, Matei D. Strother R, et al. Ther Clin Risk Manag. 2009 Jun;5(3):639-50. doi: 10.2147/tcrm.s5148. Epub 2009 Aug 20. Ther Clin Risk Manag. 2009. PMID: 19707541 Free PMC article.
• A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours.
  Attard G, Kitzen J, Blagden SP, Fong PC, Pronk LC, Zhi J, Zugmaier G, Verweij J, de Bono JS, de Jonge M. Attard G, et al. Br J Cancer. 2007 Nov 19;97(10):1338-43. doi: 10.1038/sj.bjc.6604043. Epub 2007 Nov 13. Br J Cancer. 2007. PMID: 18000498 Free PMC article. Clinical Trial.
• Astragaloside attenuates the progression of prostate cancer cells through endoplasmic reticulum stress pathways.
  Tan B, Jia R, Wang G, Yang J. Tan B, et al. Oncol Lett. 2018 Sep;16(3):3901-3906. doi: 10.3892/ol.2018.9071. Epub 2018 Jul 4. Oncol Lett. 2018. PMID: 30128005 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal